Fairvalue-Calculator Fairvalue-Calculator
EN DE

Edesa Biotech, Inc (EDSA) Fair Value & Analysis

Healthcare · US · Market cap $65.4M

Price$7.64
Fair Value$6.30
Upside-17.5%
Quality95/100
Evidence: Low Range $4.73 – $7.88

Fair value as of: Jun 24, 2026

Analysis

Edesa Biotech, Inc (EDSA) currently trades at $7.64, while our model-based Fair Value estimate is $6.30 — implying the stock looks roughly 17.5% overvalued today. We read business quality at 95/100 (high quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: low).

About the company

Edesa Biotech, Inc., a clinical-stage biopharmaceutical company, engages in the research and development, manufacture, and commercialization of pharmaceutical products for inflammatory and immune-related diseases. It develops EB05, a monoclonal antibody, which is in Phase 3 clinical study for the treatment of acute respiratory distress syndrome; and EB01, a topical vanishing cream containing non-steroidal anti-inflammatory compound that has completed Phase 3 clinical study to treat chronic allergic contact dermatitis. The company develops EB07, a monoclonal antibody, which is in a Phase 2 clinical study for the treatment of pulmonary fibrosis; and EB06, a human monoclonal antibody candidate that binds to chemokine ligand 10 (CXCL10) and inhibits the interaction of CXCL10 with its receptors, CXCR3A, and CXCR3B. It has a collaboration agreement with NovImmune SA to develop monoclonal antibodies targeting products containing toll-like receptor 4 and CXCL10 for therapeutic, prophylactic…

Open the full interactive analysis →

Similar stocks

Vertex Pharmaceuticals Incorporated (VRTX34) -38% Regeneron Pharmaceuticals, Inc (REGN) -14% UCB SA (UCB) -28% argenx SE (ARGNF) -57% Samsung Biologics Co (207940) -28% Alnylam Pharmaceuticals, Inc (ALNY) -63%

Frequently asked questions

Is Edesa Biotech, Inc (EDSA) undervalued?
As of Jun 24, 2026, our model estimates a fair value of $6.30 versus a price of $7.64 — about −18% (overvalued). Model-based estimate, not financial advice.
What is the fair value of EDSA?
Our 21-model fair value for Edesa Biotech, Inc is $6.30 (as of Jun 24, 2026), built from audited fundamentals. The current price is $7.64.
What is the quality score of EDSA?
Edesa Biotech, Inc has a Quality Score of 95/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.